FeesSafety
Pluang+

Lifecore Biomedical Q3 2026 revenues fall 18.6%, but new projects boost future growth prospects.

Company Fundamentals
04 Nov 2026, 14:05 WIB
GlobeNewsWire
View Source
Neutral
Lifecore Biomedical Q3 2026 revenues fall 18.6%, but new projects boost future growth prospects.

Lifecore Biomedical reported a Q3 2026 revenue decline of 18.6% to $25.3 million, with a net loss of $40.1 million driven by increased expenses and debt-related costs. Despite the financial setback, the company secured several new technology transfer and development projects expected to contribute to long-term revenue growth starting in 2027. Operating expenses decreased by 28.9%, and adjusted EBITDA rose to $4.0 million, signaling operational improvements. Lifecore ended the quarter with $38 million in liquidity, positioning it to support its growing project pipeline and future expansion.

Lifecore Biomedical's Q3 2026 financial results provide context for readers interested in health sector trends. On November 4, 2026, out of 150 health-sector US stocks tradable on Pluang, 118 advanced while 24 declined. Notable gainers included RVTY at USD 173.82 with a 6.32% rise and 100% buy orders, NUVB at USD 4.98 up 6.18%, and CGC at USD 0.75 increasing 6.13% with a typical hold time of 40 days, as of 18:41 WIB.

More News

Kelly Technology + Motion Recruitment named Leader by Everest Group for US IT staffing and consulting excellence

Kelly Technology + Motion Recruitment named Leader by Everest Group for US IT staffing and consulting excellence

Kelly Technology + Motion Recruitment, a division of Kelly Services, has been recognized as a Leader on Everest Group's 2026 U.S. IT Contingent Talent and Strategic Solutions PEAK Matrix® for its expertise in specialized IT staffing, consulting, and ...

Market News
Bullish
32 minutes ago
Sutro Biopharma to present at multiple investor conferences in November and December 2026

Sutro Biopharma to present at multiple investor conferences in November and December 2026

Sutro Biopharma, a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), announced its participation in several investor conferences in November and December 2026, including events hosted by Stifel, Truist Securities, UBS, ...

Market News
Neutral
1 hour ago
etoro acquires Argentine fintech LB Finanzas to expand in Latin America

etoro acquires Argentine fintech LB Finanzas to expand in Latin America

etoro has agreed to acquire LB Finanzas, a leading Argentine all-in-one financial app, to strengthen its presence in Latin America's fast-growing fintech market. LB Finanzas offers integrated investing and payment solutions, catering to Argentine ret...

Company Fundamentals
Bullish
1 hour ago
JD.com to release Q3 2026 financial results on Nov 17 with a management call scheduled.

JD.com to release Q3 2026 financial results on Nov 17 with a management call scheduled.

JD.com announced it will publish its unaudited financial results for the third quarter of 2026 on November 17, before the U.S. market opens. The company's management will hold a conference call the same day to discuss the results, providing investors...

Company Fundamentals
Neutral
4 hours ago
KE Holdings to release Q3 2026 financial results on Nov 16 with a live earnings call.

KE Holdings to release Q3 2026 financial results on Nov 16 with a live earnings call.

KE Holdings Inc., a major online and offline housing platform in China, will announce its unaudited financial results for the third quarter of 2026 on November 16 before the U.S. market opens. The company will host an earnings conference call at 7:00...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App